Use of FGF21 / GLP-1 fusion proteins

By using the FGF21/GLP-1 fusion protein to prepare drugs, the problem of existing treatments being unable to effectively control blood sugar and side effects has been solved, achieving effective treatment and functional improvement for diseases such as type 2 diabetes.

CN122140897APending Publication Date: 2026-06-05SUNSHINE LAKE PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
SUNSHINE LAKE PHARMA CO LTD
Filing Date
2025-12-03
Publication Date
2026-06-05

AI Technical Summary

Technical Problem

Existing treatments for type 2 diabetes, obesity, fatty liver disease, steatohepatitis, and dyslipidemia cannot completely control blood sugar levels and may be accompanied by side effects. The efficacy and safety of fusion proteins are affected by a variety of factors.

Method used

An FGF21/GLP-1 fusion protein is provided for the preparation of drugs that, by administering pharmaceutically acceptable doses to individuals in need, reduce indicators such as HbA1c, blood glucose, body weight, and liver fat content, or improve adiponectin, insulin sensitivity, and β-cell function.

Benefits of technology

It effectively treats type 2 diabetes, obesity, fatty liver disease, steatohepatitis, and dyslipidemia, reduces related indicators, improves related functions, and maximizes treatment effectiveness while minimizing risks.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure HDA0005721564460000011
    Figure HDA0005721564460000011
Patent Text Reader

Abstract

The present application discloses the use of FGF21 / GLP-1 fusion proteins in the preparation of a medicament for preventing and / or treating at least one of type 2 diabetes, obesity, steatohepatitis, and triglyceridemia. The FGF21 / GLP-1 fusion proteins of the present application are effective in treating at least one of type 2 diabetes, obesity, steatohepatitis, and triglyceridemia, and in particular, can reduce at least one of HbA1c, blood glucose, body weight, liver fat content, ALT, AST, glutamyl transpeptidase, triglyceride, total cholesterol, low-density lipoprotein cholesterol, or increase at least one of adiponectin, insulin sensitivity, and beta-cell function in the subject.
Need to check novelty before this filing date? Find Prior Art